Is it justifiable to move the grade-1 ki67 index cut-off from 3% to 5% for pancreatic neuroendocrine tumors as has been proposed? The cases that fall to 3-5% category have clinicopathologic characteristics closer to those > 5%

Basit Öğe Kaydı
dc.authorid0000-0001-6830-7701
dc.contributor.authorReid, Michelle
dc.contributor.authorBalcı, Serdar
dc.contributor.authorBağcı, Pelin
dc.contributor.authorSaka, Burcu
dc.contributor.authorPehlivanoğlu, Burçin
dc.contributor.authorErbarut Seven, İpek
dc.contributor.authorBaştürk, Olca
dc.contributor.authorAdsay, N. Volkan
dc.date.accessioned2020-04-16T08:12:53Z
dc.date.available2020-04-16T08:12:53Z
dc.date.issued2020
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Tıbbi Patoloji Ana Bilim Dalı
dc.description.abstractBackground: Grading of linear parameters into meaningful (clinically relevant) clusters is a well-known challenge. Recently several groupshave proposed to change the Ki67 index cut-off for grade 1 (G1) category for PanNETs from < 3% to < 5%. This proposal presupposes thatthe cases with Ki67 index of 3-5% are NOT clinically different than the 0-3% group and thus can be lumped together with the current G1 (0-3% cases), instead of their current home in the G2 category (> 3%).
dc.description.sponsorshipUnited States & Canadian Academy of Pathologyen_US
dc.identifier.citationReid, M., Balcı, S., Bağcı, P., Saka, B., Pehlivanoğlu, B., Erbarut Seven, İ. ... Adsay, N. V. (2020). Is it justifiable to move the grade-1 ki67 index cut-off from 3% to 5% for pancreatic neuroendocrine tumors as has been proposed? The cases that fall to 3-5% category have clinicopathologic characteristics closer to those > 5%. 109th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) içinde (1673-1673. ss.). Los Angeles, CA, February 29-March 05, 2020.
dc.identifier.endpage1673
dc.identifier.issn0893-3952
dc.identifier.issn1530-0285
dc.identifier.issueSupplement: 2
dc.identifier.startpage1673
dc.identifier.urihttps://hdl.handle.net/20.500.12511/5129
dc.identifier.volume33
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherNature Publishing Group
dc.relation.ispartof109th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP)en_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectPancreatic Neuroendocrine
dc.subjectClinicopathologic
dc.subjectKi67 Index
dc.titleIs it justifiable to move the grade-1 ki67 index cut-off from 3% to 5% for pancreatic neuroendocrine tumors as has been proposed? The cases that fall to 3-5% category have clinicopathologic characteristics closer to those > 5%
dc.typeConference Object

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Saka,Burcu-2020.pdf
Boyut:
124.25 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Bildiri Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu